409 related articles for article (PubMed ID: 32935575)
1. Relief of Lower Urinary Tract Symptoms After MRI-Guided Transurethral Ultrasound Ablation for Localized Prostate Cancer: Subgroup Analyses in Patients with Concurrent Cancer and Benign Prostatic Hyperplasia.
Elterman D; Li W; Hatiboglu G; Relle J; Zorn KC; Bhojani N; Chin J
J Endourol; 2021 Apr; 35(4):497-505. PubMed ID: 32935575
[No Abstract] [Full Text] [Related]
2. Magnetic resonance imaging-guided transurethral ultrasound ablation for benign prostatic hyperplasia: 12-month clinical outcomes of a phase I study.
Viitala A; Anttinen M; Wright C; Virtanen I; Mäkelä P; Hovinen T; Sainio T; Saunavaara J; Taimen P; Blanco Sequeiros R; Boström PJ
BJU Int; 2022 Feb; 129(2):208-216. PubMed ID: 34161649
[TBL] [Abstract][Full Text] [Related]
3. Magnetic Resonance Imaging-Guided Transurethral Ultrasound Ablation of Prostate Tissue in Patients with Localized Prostate Cancer: A Prospective Phase 1 Clinical Trial.
Chin JL; Billia M; Relle J; Roethke MC; Popeneciu IV; Kuru TH; Hatiboglu G; Mueller-Wolf MB; Motsch J; Romagnoli C; Kassam Z; Harle CC; Hafron J; Nandalur KR; Chronik BA; Burtnyk M; Schlemmer HP; Pahernik S
Eur Urol; 2016 Sep; 70(3):447-55. PubMed ID: 26777228
[TBL] [Abstract][Full Text] [Related]
4. Single center retrospective analysis of fifty-two prostate cancer patients with customized MR-guided transurethral ultrasound ablation (TULSA).
Lumiani A; Samun D; Sroka R; Muschter R
Urol Oncol; 2021 Dec; 39(12):830.e9-830.e16. PubMed ID: 34144892
[TBL] [Abstract][Full Text] [Related]
5. Effects of tadalafil on lower urinary tract symptoms secondary to benign prostatic hyperplasia and on erectile dysfunction in sexually active men with both conditions: analyses of pooled data from four randomized, placebo-controlled tadalafil clinical studies.
Porst H; Roehrborn CG; Secrest RJ; Esler A; Viktrup L
J Sex Med; 2013 Aug; 10(8):2044-52. PubMed ID: 23782459
[TBL] [Abstract][Full Text] [Related]
6. Prostate Artery Embolization for Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia: Results From a Prospective FDA-Approved Investigational Device Exemption Study.
Salem R; Hairston J; Hohlastos E; Riaz A; Kallini J; Gabr A; Ali R; Jenkins K; Karp J; Desai K; Thornburg B; Casalino D; Miller F; Hofer M; Hamoui N; Mouli S
Urology; 2018 Oct; 120():205-210. PubMed ID: 30036614
[TBL] [Abstract][Full Text] [Related]
7. Prostatic Urethral Lift: A New Minimally Invasive Treatment for Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia.
Bozkurt A; Karabakan M; Keskin E; Hirik E; Balci MB; Nuhoglu B
Urol Int; 2016; 96(2):202-6. PubMed ID: 26613256
[TBL] [Abstract][Full Text] [Related]
8. [The results of the multicenter prospective comparative study of Androgel in men with endogenous testosterone deficiency and lower urinary tract symptoms, associated with benign prostate hyperplasia (POTOK)].
Kogan MI; Avadieva NE; Gevorkyan LS; Loginov YA; Metelkin AM; Mitin AA; Patrikeev AA
Urologiia; 2023 May; (2):32-40. PubMed ID: 37401702
[TBL] [Abstract][Full Text] [Related]
9. Focal therapy for localised unifocal and multifocal prostate cancer: a prospective development study.
Ahmed HU; Hindley RG; Dickinson L; Freeman A; Kirkham AP; Sahu M; Scott R; Allen C; Van der Meulen J; Emberton M
Lancet Oncol; 2012 Jun; 13(6):622-32. PubMed ID: 22512844
[TBL] [Abstract][Full Text] [Related]
10. Five-year outcomes for Aquablation therapy compared to TURP: results from a double-blind, randomized trial in men with LUTS due to BPH.
Gilling PJ; Barber N; Bidair M; Anderson P; Sutton M; Aho T; Kramolowsky E; Thomas A; Kaufman RP; Badlani G; Plante M; Desai M; Doumanian L; Te AE; Roehrborn CG
Can J Urol; 2022 Feb; 29(1):10960-10968. PubMed ID: 35150215
[TBL] [Abstract][Full Text] [Related]
11. Magnetic Resonance Imaging-Guided Transurethral Ultrasound Ablation of Prostate Cancer: A Systematic Review.
Dora C; Clarke GM; Frey G; Sella D
J Endourol; 2022 Jun; 36(6):841-854. PubMed ID: 35029127
[No Abstract] [Full Text] [Related]
12. First-in-man Safety and Efficacy of the ClearRing Implant for the Treatment of Benign Prostatic Hyperplasia.
Vjaters E; Nitsan D; Mullerad M; Engelstein D; Leibovitch I; Feld Y
Eur Urol Focus; 2020 Jan; 6(1):131-136. PubMed ID: 30293945
[TBL] [Abstract][Full Text] [Related]
13. Aquablation - image-guided robot-assisted waterjet ablation of the prostate: initial clinical experience.
Gilling P; Reuther R; Kahokehr A; Fraundorfer M
BJU Int; 2016 Jun; 117(6):923-9. PubMed ID: 26477826
[TBL] [Abstract][Full Text] [Related]
14. Clinical Effects of Oral Supplementation of Gamma-Cyclodextrin Curcumin Complex in Male Patients with Moderate-To-Severe Benign Prostatic Hyperplasia-Related Lower Urinary Tract Symptoms.
Crocerossa F; Cantiello F; Bagalá L; Sicoli F; Carbonara U; Manfredi C; Falagario U; Veccia A; Pandolfo SD; Napolitano L; Ferro M; Di Dio M; Mondaini N; Damiano R
Urol Int; 2023; 107(10-12):924-934. PubMed ID: 37939691
[TBL] [Abstract][Full Text] [Related]
15. Rezum water vapor therapy for patients with mild, moderate, or severe lower urinary tract symptoms: A retrospective study in a multiethnic population.
Babar M; Loloi J; Tang K; Singh S; Ines M; Patel RD; Iqbal N; Ciatto M
Prostate; 2023 May; 83(7):713-721. PubMed ID: 36879380
[TBL] [Abstract][Full Text] [Related]
16. Prostate artery embolisation: an all-comers, single-operator experience in 159 patients with lower urinary tract symptoms, urinary retention, or haematuria with medium-term follow-up.
Thulasidasan N; Kok HK; Elhage O; Clovis S; Popert R; Sabharwal T
Clin Radiol; 2019 Jul; 74(7):569.e1-569.e8. PubMed ID: 30955835
[TBL] [Abstract][Full Text] [Related]
17. The prostatic urethral lift for the treatment of lower urinary tract symptoms associated with prostate enlargement due to benign prostatic hyperplasia: the L.I.F.T. Study.
Roehrborn CG; Gange SN; Shore ND; Giddens JL; Bolton DM; Cowan BE; Brown BT; McVary KT; Te AE; Gholami SS; Rashid P; Moseley WG; Chin PT; Dowling WT; Freedman SJ; Incze PF; Coffield KS; Borges FD; Rukstalis DB
J Urol; 2013 Dec; 190(6):2161-7. PubMed ID: 23764081
[TBL] [Abstract][Full Text] [Related]
18. Temporary implantable nitinol device (TIND): a novel, minimally invasive treatment for relief of lower urinary tract symptoms (LUTS) related to benign prostatic hyperplasia (BPH): feasibility, safety and functional results at 1 year of follow-up.
Porpiglia F; Fiori C; Bertolo R; Garrou D; Cattaneo G; Amparore D
BJU Int; 2015 Aug; 116(2):278-87. PubMed ID: 25382816
[TBL] [Abstract][Full Text] [Related]
19. Ablative minimally invasive surgical therapies for benign prostatic hyperplasia: A review of Aquablation, Rezum, and transperineal laser prostate ablation.
Nguyen DD; Li T; Ferreira R; Baker Berjaoui M; Nguyen AV; Chughtai B; Zorn KC; Bhojani N; Elterman D
Prostate Cancer Prostatic Dis; 2024 Mar; 27(1):22-28. PubMed ID: 37081044
[TBL] [Abstract][Full Text] [Related]
20. Second-generation of temporary implantable nitinol device for the relief of lower urinary tract symptoms due to benign prostatic hyperplasia: results of a prospective, multicentre study at 1 year of follow-up.
Porpiglia F; Fiori C; Amparore D; Kadner G; Manit A; Valerio M; Nicolaas L; Ho BSH; Alonso S; Schulman C; Barber N
BJU Int; 2019 Jun; 123(6):1061-1069. PubMed ID: 30382600
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
